An interventional study of Mobile-Based Perioperative Education Program and Standard Perioperative Care in Prostate Cancer (Post Prostatectomy), Urinary Incontinence (UI) and Erectile Dysfunction Following Radical Prostatectomy, sponsored by Giresun University. Recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Giresun University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Prostatic Neoplasms with a site in Turkey — 22 open to participants now, 42 under way, 21 of them phase 3. Prostatic Neoplasms · Turkey.
Among the 111 studies in Prostatic Neoplasms with a site in Turkey, this one is the 62nd largest by planned enrollment of the 90 interventional ones that give a count, is one of 13 that started in 2026, is one of 40 with no phase, reaches primary completion later than 24 of the 41 other live ones, and was the 101st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →22 of the 111 studies in Prostatic Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University Pendik Training and Research Hospital · Sites in Turkey
Ages 18–75 · Men only
AstraZeneca · Sites in Turkey, United States, Austria and 18 more countries
Ages 18+ · Men only
Ankara Etlik City Hospital · Sites in Turkey
Ages 50–75 · Men only
AstraZeneca · Sites in Turkey, United States, Australia and 21 more countries
Ages 18+ · Men only
Hoffmann-La Roche · Sites in Turkey, United States, Australia and 9 more countries
Ages 18+ · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 226 across the 90 interventional studies, 230 across the 21 observational. Of the 64 that completed or were terminated, 19 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 111 have an industry lead sponsor. The 10 most frequent:
Giresun University is the lead sponsor of 57 studies on the registry; 6 are open to participants now.
Giresun University has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Prostatic Neoplasms with a site in Turkey that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06629779Phase 3PfizerA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | 2027-09-30 |
| NCT07491198Ege UniversityEffect Of Trendelenburg Position And Pneumoperitoneum On Optic Nerve Sheath Diameter In Robot-Assisted Prostatectomy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 111 studies in Prostatic Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective randomized controlled study aims to evaluate the effect of mobile-based perioperative education on postoperative urinary incontinence and erectile function in patients undergoing radical prostatectomy. Patients scheduled for radical prostatectomy will be assigned to either an intervention group or a control group. The intervention group will receive standard care plus a structured mobile application-based perioperative education program including video-assisted pelvic floor muscle training, perioperative education modules, reminders, and follow-up components. The control group will receive routine perioperative care and standard patient education. Data will be collected preoperatively, after urinary catheter removal, and at 1 month and 3 months after surgery. The primary outcomes are urinary incontinence and erectile function, assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), the International Index of Erectile Function-5 (IIEF-5), and a 24-hour pad assessment. Secondary outcomes include lower urinary tract symptoms and disease-specific quality of life assessed by the International Prostate Symptom Score (IPSS), psychological status assessed by the Depression Anxiety Stress Scale-21 (DASS-21), and system usability assessed by the Turkish version of the Computer System Usability Questionnaire-Short Version (T-CSUQ-SV)
Prostate cancer is one of the most common malignancies in men, and radical prostatectomy is a major curative treatment option for localized disease. However, urinary incontinence and erectile dysfunction remain among the most important postoperative complications affecting patients' functional recovery and quality of life. Access to structured perioperative education and rehabilitation may be limited because of time, cost, travel burden, and restricted access to specialized support. Mobile health-based interventions may provide an accessible and scalable approach for delivering perioperative education, exercise guidance, reminders, and follow-up support.
This study is designed to evaluate the effectiveness of a mobile-based perioperative education program for patients undergoing radical prostatectomy. Participants will be assigned to either an intervention group or a control group. The intervention group will receive routine perioperative care in addition to a structured mobile application-based program that includes video-assisted pelvic floor muscle training, perioperative education content, reminder notifications, and follow-up support. The control group will receive routine perioperative care and standard patient education.
Data will be collected at four time points: before surgery, after urinary catheter removal, at 1 month after surgery, and at 3 months after surgery. The primary outcomes of the study are postoperative urinary incontinence and erectile function. Urinary incontinence will be assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and a 24-hour pad assessment. Erectile function will be evaluated using the International Index of Erectile Function-5 (IIEF-5). Secondary outcomes will include lower urinary tract symptoms and disease-specific quality of life assessed by the International Prostate Symptom Score (IPSS), psychological status assessed by the Depression Anxiety Stress Scale-21 (DASS-21), and usability of the mobile application assessed by the Turkish version of the Computer System Usability Questionnaire-Short Version (T-CSUQ-SV).
The findings of this study are expected to contribute to the development of accessible and structured perioperative care models for patients undergoing radical prostatectomy and to provide evidence on the effectiveness of mobile-based perioperative education in improving postoperative functional outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive routine perioperative care in addition to a structured mobile application-based perioperative education program including video-assisted pelvic floor muscle training, perioperative education content, reminders, and follow-up support.
Behavioral: Mobile-Based Perioperative Education Program
Participants will receive routine perioperative care and standard patient education.
Other: Standard Perioperative Care
A structured mobile application-based perioperative education program including video-assisted pelvic floor muscle training, perioperative education content, reminder notifications, and follow-up support.
Routine perioperative care and standard patient education provided according to institutional practice.
Urinary Incontinence Severity
Urinary incontinence severity will be assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF). Higher scores indicate greater symptom severity and greater impact on quality of life.
Time frame: Before surgery, after urinary catheter removal, at 1 month after surgery, and at 3 months after surgery
Erectile Function
Erectile function will be assessed using the International Index of Erectile Function-5 (IIEF-5). Higher scores indicate better erectile function.
Time frame: Before surgery, after urinary catheter removal, at 1 month after surgery, and at 3 months after surgery
Urinary Leakage Severity by 24-Hour Pad Use
Urinary leakage severity will be evaluated according to 24-hour pad use. Daily use of 1 to 2 pads will be classified as mild, 3 to 5 pads as moderate, and more than 5 pads as severe urinary incontinence.
Time frame: After urinary catheter removal, at 1 month after surgery, and at 3 months after surgery
Lower Urinary Tract Symptoms and Disease-Specific Quality of Life
Assessed using the International Prostate Symptom Score (IPSS), including symptom severity and the disease-specific quality of life item.
Time frame: Before surgery, after urinary catheter removal, at 1 month after surgery, and at 3 months after surgery
Psychological Status
Assessed using the Depression Anxiety Stress Scale-21 (DASS-21).
Time frame: Before surgery, after urinary catheter removal, at 1 month after surgery, and at 3 months after surgery
System Usability
Usability of the mobile application will be assessed using the Turkish version of the Computer System Usability Questionnaire-Short Version (T-CSUQ-SV) to evaluate participants' ability to use the mobile application.
Time frame: Before surgery
Plan to share: No — No plan has been established to share individual participant data with other researchers.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Giresun University